What is it about?
Our research is about the applicability and usefulness of immunohistochemically analyzed expression of proliferative markers Ki-67 and PCNA, cell cycle markers pRb and p16, and apoptotic markers p53, Bcl-2 and Bax in esophageal adenocarcinoma and Barrett’s associated dysplasia.
Featured Image
Why is it important?
The results form our work showed that ninefold higher risk to develop EAC exists for the patient with strong p53 expression. Interestingly, patients with strong p53 expression survived 6.8 months longer than the patients with weak p53 expression and 8.6 months longer than the patients with moderate p53 expression. No correlation was found between the expression of the other markers and prognosis.
Perspectives
I hope that our work could contribute to the revealing of molecular changes in esophageal adenocarcinoma.
Dr Andrey Iskrenov Kotzev
Medicinski universitet Sofia
Read the Original
This page is a summary of: Immunohistochemical Expression of Ki-67, PCNA, pRb, p16, p53, Bcl-2 and Bax in Esophageal Adenocarcinoma and Barrett’s Associated Dysplasia, Journal of Cancer Therapy, January 2012, Scientific Research Publishing, Inc,,
DOI: 10.4236/jct.2012.36143.
You can read the full text:
Contributors
The following have contributed to this page
